Opioid Antagonist Market size is expected to reach USD 15 Billion by the end of 2036, growing at a CAGR of 13% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of opioid antagonists was over USD 3 Billion. Ongoing research and development efforts within the pharmaceutical industry have been dedicated to enhancing the usability and effectiveness of opioid antagonists, particularly in addressing opioid overdoses. One notable advancement involves the evolution of formulations and delivery methods, exemplified by the creation of nasal sprays and auto-injectors specifically designed for naloxone administration. Estimates indicate that the rate of naloxone administrations rose by almost 75%, from 573 to 1004 per 100,000 EMS incidents. This increase is consistent with a 79% rise in the age-adjusted opioid death rate.
Further, The expansion of opioid antagonist applications beyond immediate overdose reversal has significantly impacted market growth. Naltrexone, originally recognized for its role in blocking opioid receptors, has diversified its application, particularly in addressing addiction. Its effectiveness in preventing relapse among individuals grappling with opioid or alcohol dependence has broadened its market potential. Injectable naltrexone was used in 13% of medical programs for Alcohol Use Disorder Treatment , and 3% of programs for opioid use disorder, according to Research Nester Analysts' analysis.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~ 13% |
|
Base Year Market Size (2023) |
~ USD 3 Billion |
|
Forecast Year Market Size (2036) |
~ USD 15Billion |
|
Regional Scope |
|
Drug Type (Buprenorphine, Naltrexone, Bunavail)
The buprenorphine segment is estimated to hold 52% share of the global opioid antagonist market by 2036. Primarily owing to its excellent clinical profile. In 2020, an estimated 1.7 million individuals reported taking buprenorphine as directed by doctor. The drug has great efficiency in managing addiction, with low potential for abuse as well as relatively mild adverse effects and its favorable formulary coverage are some of the factors that can be attributed to the high adoption of this drug.
End User (Hospitals, Private Clinics)
The hospital segment in the opioid antagonist market is anticipated to garner significant growth during the forecast period, owing to the increasing patient pool for opium and alcohol dependency. Moreover, the critical condition of the individual addicted to drugs, and the need for specific treatment is estimated to boost the segment’s growth.
Our in-depth analysis of the global market includes the following segments:
|
Drug Type |
|
|
End User |
|
North American Market Forecast
North American opioid antagonist market is estimated to account for 38 % of the revenue share by 2036. The region has emerged as a significant producer of Naloxone, a primary antagonist used for reversing opioid overdoses which has become more accessible through governmental initiatives, community distribution programs, and increased awareness campaigns. The region's high prevalence of opioid addiction and overdose deaths has prompted regulatory bodies to streamline approval processes for opioid antagonists, fostering a competitive market landscape. Between 2020 and 2021, there was a more than 16% rise in the number of drug overdose deaths. Opioids accounted for more than 75% of the roughly 107,000 drug overdose deaths in 2021. Pharmaceutical companies have expanded research and development efforts, focusing on innovative formulations such as nasal sprays and auto-injectors to enhance ease of use in emergencies.
APAC Market Statistics
Asia Pacific opioid antagonist market is slated to hold a significant revenue share during the forecast period. The region’s market reflects a diverse landscape shaped by varying degrees of opioid misuse and regulatory environments across countries. While countries like Australia and New Zealand have established robust programs promoting naloxone distribution to combat opioid overdoses, other nations within the region face challenges in acknowledging and addressing opioid abuse. Cultural stigma, limited healthcare infrastructure, and differing levels of awareness contribute to disparities in opioid antagonist adoption.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?